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ABSTRACT 
 
Ear diseases can significantly affect the quality of life of people, so the need for effective 
treatment encourages the development of new active substances and new dosage forms. Otic 
dosage forms may be solutions, suspensions, or emulsions of drops or spray for washing the 
ear or for administration to the ear canal. They may be ear-wash preparations in the form of 
solution or emulsion, or semi-solid preparations of gel, cream or ointment form, or 
preparations in the form of powders, sticks or buffers. These preparations may contain one or 
more active ingredients in a suitable vehicle. In addition to the active ingredient, isotonisation, 
pH adjustment, viscosity or solubility enhancement, buffering, preservation, etc. excipients 
may be included forthe above mentioned purposes. These substances should not alter the 
pharmacological effect of the active substance and should not be toxic or irritating. Ear 
preparations can be packaged in single or multiple doses. It is anticipated that otic dosage 
forms will be improved and the importance of non-invasive, safe and highly controlled drug 
delivery systems will increase in the future. 
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INTRODUCTION 
 
Potentially life-threatening infections, especially for immunocompromised host, may spread 
to the surrounding tissues if not optimally treated. Otic dosage forms are used to treat external 
ear and auditory canal infections among them. In addition to infections, otic dosage forms are 
often used against ear diseases such as acute or chronic otitis media, hearing loss, tinnitus, and 
Meniere's disease [1]. According to World Health Organization criteria, 25 dB loss in hearing 
frequency pure tone average in both ears is defined as hearing loss and this negatively affects 
the communication of the individual in daily life. Around 300 million people worldwide have 
moderate or severe hearing loss, and this figure is expected to reach 900 million by 2050 [2, 
3]. The human ear consists of 3 parts as outer, middle and inner ones. The sound waves 
reaching the outer ear cause the eardrum in the middle ear to vibrate. These vibrations are 
transmitted to the inner ear with the help of bones. Here, the vibrations are translated by the 
snail, the original hearing organ, into nerve signals that the brain perceives [4]. Many diseases 
such as ear pain, otitis media, otitis externa, Meniere's disease, tinnitus, ear wax, tympanic 
membrane perforation, acoustic neuroma, mastoiditis, benign paroxysmal positional vertigo, 
cholesteatoma can affect any of these three main sections. Otitis media is the most common 
ear disease [5, 6]. Otitis externa, known as swimmer's ear, affecting the outer ear, can be seen 
with or without infection throughout the ear canal. It can be subdivided into acute (less than 6 
weeks), recurrent acute and chronic (more than 3 months).The most common clinical case 
among these is acute otitis externa whose cause isa bacterial infection (90% of cases) or a 
fungal infection (10% of cases) [7]. The most prominent feature of this disease is the local 
feeling of discomfort in the external auditory canal, redness of the canal and swelling with 
variable flowing. The causes of acute otitis externa can also be associated with various non-
infectious systemic or local dermatological processes [8,9]. 
 
  
Local anesthetics, cleaning agents (peroxides), anti-infectives and antifungals are among the 
commonly used categories of otic drugs for the human ear. Doses of these drugs can be in 
liquid, ointment, gel or powder forms. Otic solutions and suspensions in liquid dosage form 
are prepared for administration into the ear. The solutions are also used to wash the ear. Otic 
wash solutions such as surfactants, weak sodium bicarbonate, boric acid (0.5-1%) or 
aluminum acetate may be heated to about 37 °C before being placed in the ear to 
accommodate body temperature. These washing solutions; usually used to remove ear wax, 
infected fluids and foreign bodies from the ear canal. If a long period of drug action is 
required for the treatment of ear infection, otic suspensions in which the active ingredient is 
not dissolved in the liquid are used. Otic ointments and gels containing antibacterial, 
antifungal or corticosteroid components are semi-solid preparations that are rarely used but 
are applied outside the ear. These ointments are applied directly to the outer parts of the ear. 
Insufflation as solid preparations in the form of finely divided powders is applied to the ear 
canal. However, the application of a powder into the ear canal is not very common, since the 
ear is free of fluids and dust-plug accumulation may occur. The finely divided powders may 
comprise an antibacterial and/or an antifungal agent which will form a depot for the 
medicament. A small rubber or plastic bulb can be used as a powder blower for this 
purpose[10]. 
 
 
TOPICAL DRUG APPLICATIONS IN OTIC FIELD 
 
In general, dosage forms for topical otic drug administration are eardrops, foams, gels, creams 
and ointments [11]. The active ingredients may be dissolved or dispersed in water or diluted 
alcohol, particularly polypropylene glycol and anhydrous glycerin. Among the carriers, 
polypropylene glycol is inexpensive but it shouldn’t be forgotten that it has an ototoxic effect. 
Carriersshould exhibit the properties of especially softening the earwax and skin, inert, non-
irritating and viscous vehicle properties that extend the contact time of the active material 
with the ear canal surface. The viscosity of a topical formulation is important because the 
drug must be able to reach the site of infection effectively. Agents to increase formulation 
viscosity may be added to protect the formulations in the ear. Otic foams are commonly used 
to increase drug contact time in the ear canal [12,13]. Because the dose volume applied to the 
otic site is low, the concentration of the drug to be prepared should be high, so that the 
solubility of the active substance is taken into consideration when selecting the solvent. 
Generally, topical otic preparations are prepared in the form of acidic solutions or suspensions 
with a pH of 3-4 for inhibition of bacterial growth. Commonly used excipients are 
summarized in Table 1, based on the FDA inactive content database and on the market-
approved current otic products [14,15]. 
 
Table 1. Commonly used excipients for topical otic drug delivery systems. 
 
Function category Excipients Dosage forms 
pH adjusting agents Acetic acid 
Calcium carbonate 
Citric acid 
Hydrochloric acid 
Benzyl alcohol 
Lactic acid 
Monopotassium phosphate 
Sodium acetate 
Sodium borate 
Sodium citrate 
Solution, suspension, 
liquid, drops 
  
Sodium phosphate, dibasic, monobasic 
Sodium hydroxide 
Sulfuric acid 
Tris(Hydroxymethyl)aminomethane 
Antimicrobial 
preservatives 
Aluminum acetate 
Benzalkonium chloride 
Benzethonium chloride 
Benzyl alcohol 
Boric acid 
Chlorobutanol 
Isopropyl alcohol 
Phenethyl alcohol 
Methylparaben 
Potassium metabisulfite 
Propylparaben 
Suspension agents Aluminum sulfate 
Cetyl alcohol 
Hydroxyethyl cellulose 
Methylparaben 
Polyvinyl alcohol 
Stabilizing and 
thickening agents 
Creatinine 
Hydrogenated soybean lecithin 
Polyvinylpyrrolidone K30 
Polyvinylpyrrolidone K90 
Poloxamer 407 
Softeners Cupric sulfate 
Glycerol 
Polyoxyl 40 Stearate 
Solvent agents / 
Wetting agents 
Polysorbate 20 
Polysorbate 80 
Tyloxapol 
Tonicity adjusters Sodium chloride 
Sodium sulfite 
Ointment base Mineraloil 
Peanutoil 
Petrolatum 
Oil,ointment 
 
Physicochemical Properties 
 
Physicochemical factors such as solubility, viscosity, tonicity, surfactant and preservative 
properties, serum diffusion activity, impregnation properties, serumolytic activity and 
rheological properties play an important role in the development of otic preparations [16]. 
Although sterility is generally ignored, products must be clean. In the carriers commonly used 
for the preparation of these products, many active substances are soluble. However, if an 
active substance does no dissolve or there are more than one active substance which are 
insoluble in these carriers or they have different solubility profiles, the product can also be 
prepared as a suspension. Since most of these carriers are relatively viscous agents, the 
addition of defloculating agents may not be necessary. The optimum viscosity of the 
preparation that increases the contact time of the active agent with the ear surface and 
provides avoidance from the leakage from the ear is important for sufficient pharmacological 
activity. If the viscosity of the preparation is low, the contact time will be short. On the other 
hand, if the drug is very viscous, it may not reach the inner parts of the ear or the delivery of 
the active substance to the intended site may be delayed [17]. 
  
 
The tonicity and hygroscopicity properties are important because they help drawing liquid 
from the immediate area of the ear. If the product is hypertonic, some liquid may be drawn 
from the ear, thereby releasing some of the pressure. However, if the product is hypotonic, 
there may be some fluid flow into the area. The presence of a surfactant in the preparation 
helps to spread the drug and break the cerumen, as there are often difficult conditions to clean 
the ear. This also facilitates the removal of impurities. Microbial contamination does not 
occur in otic preparations due to the high concentrations of substances such as glycerin, 
propylene glycol, polyethylene glycol 300 or 400. If these agents are not present, 
preservatives should be added to minimize microbial contamination. Some liquid otic 
preparations also need to be protected against microbial growth. When protection is required, 
agents such as chlorobutanol (0.5%), thimerosal (0.01%), and combinations of parabens are 
commonly used. Antioxidants such as sodium bisulfite, dehumidifying agents and other 
stabilizers that reduce the moisture necessary for bacteria to survive, such as isopropyl 
alcohol, are also included in the otic formulations, when necessary. Ear preparations are 
usually packaged in small (5 to 15 mL) glass or dropper plastic containers [10, 18, 19]. 
 
 
 
Advantages and Disadvantages 
 
Topical drug delivery systems have long played an important role in the treatment of ear 
diseases. This treatment includes direct administration of a drug to the ear canal. Commonly 
used topical drugs include topical antibiotics and drop-shaped antifungal drugs, gels or foams 
[15, 20, 21]. Topical drug administration to the otic area provides several advantages [22]. 
The most important advantage is that a higher local drug concentration is achieved than can 
be achieved by systemic administration. This is usually necessary for therapeutic purposes; 
for example, removal of biofilm bacteria requires an antibiotic concentration of 10-1000 times 
higher than that of planktonic bacteria. Other advantages of topical drug administration 
include rapid dispersion, good patient compliance and the ability to combine different drugs 
into a single formulation. The most important disadvantage of topical drug administration is 
the potential ototoxicity of some drugs, especially if the drug concentration is too high [23]. 
 
Quality control 
 
While performing quality control studies, standard quality control procedures such as active 
substance identification and quantification, volume / weight, pH, viscosity, density, 
appearance and sometimes odor control are followed. 
 
 
 
 
ADVANCED LOCAL TOPICAL OTIC MEDICINE RELEASE SYSTEMS 
 
Significant progress has been made in the distribution of otic drugs in the last decade. In the 
past few years, patent applications have been filed on new compounds and drug delivery 
systems for the treatment of inner ear diseases. A better understanding of the mechanisms of 
inner ear diseases has led to the development of new drugs targeting voltage-gated potassium 
ion channels, glutamate receptors, and notch developmental signaling pathway inhibitors to 
treat hearing loss, tinnitus, and peripheral vestibular dysfunction [24, 25]. 
 
Local drug administration to the inner ear was first used more than half a century ago for the 
treatment of meniere's disease with local anesthetics and antibiotics. In the 1990s, locally 
  
administered gentamicin became widespread when it was recognized that it provided an 
effective treatment for vestibular symptoms in patients with limited hearing risk and 
meniere’s disease. In addition to aminoglycosides and anesthetics, a variety of drugs have 
been administered to the round window region of the inner ear in humans, including 
neurotransmitters and neurotransmitter antagonists for tinnitus, monoclonal antibodies for 
autoimmune inner ear disease, or apoptosis inhibitors (AM-111) for noise-induced hearing 
loss. However, although the evidence supporting the use of glucocorticoids is limited, they 
have become the most widely used drugs for local administration to the inner ear and have 
been used for the treatment of Ménière's disease, idiopathic sudden sensorineural hearing loss, 
autoimmune inner ear disease, and tinnitus. Currently, the choice of dosage protocols and 
drug systems is almost entirely empirical, and there is still limited knowledge of the 
pharmacokinetics of drugs administered to the ear [26, 27]. 
 
Local application to the ear is essential for sustained drug release to the round window region 
(Fenestra cochleae). In a guinea pig model, El Kechai et al. have developed a hyposuronic 
acid liposomal gel for continuous delivery of a corticoid to the inner ear after local middle ear 
injection. It was observed that the gel remained at the injection site and round window for a 
long time without affecting the hearing thresholds of the animal. The presence of liposomes in 
the formulation was able to achieve sustained drug release for 30 days [28]. 
 
Yu et al. have developed a hydrogel formulation in the form of an injectable PEG-Silk 
structure to provide sustained release of glucocorticoid. According to the results, the 
glucocorticoid concentration in the ear is above 100 ng/mL for at least 10 days when the 
PEG-Silk formulation is used, whereas for the control formulation containing free 
glucocorticoid it is less than 12 hours [29]. 
 
With new therapies using new polymers and nanoparticles, alternative strategies are provided 
to improve drug delivery through the inner ear membrane and to target specific sites in the 
inner ear [30, 31]. Yoon et al. have developed Arg8 conjugated nanoparticles as a controlled 
drug delivery system for the treatment of diseases in the inner ear. The results of the study 
show that the prepared nanoparticles are a promising formulation for drug or gene release 
[32]. It has been reported that the preparation of nanoparticle systems in a hydrogel increases 
the nano-carrier retention time in the middle ear, thereby increasing drug concentration in the 
inner ear. In a study by Lajud et al.,a nanohydrogel formulation in which the liposome is 
contained in a chitosan hydrogel has been developed [33]. They demonstrated that 
nanohydrogel was able to achieve a controlled and sustained release of the active substance, 
and by in vivo studies that liposomes were introduced into the periliphatic area and reached 
the cellular structures of the scale media. 
 
Zhang X, Chen G et al. have developed new multiple agents loaded with poly (D, L-lactide-
coglycolide acid) (PLGA) nanoparticles and evaluated their potential for drug delivery to the 
brain through inner ear administration. PLGA nanoparticles loaded with salvianolic acid B 
(Sal B), tanshinone IIA (TS IIA) and panax notoginsenoside (PNS) were prepared by double 
emulsion / solvent evaporation method. Optimized nanoparticles were shown to exhibit 
satisfactory encapsulation efficiency and desired sustained release properties. After 
intratympanic administration (IT) in guinea pigs, the distribution of drugs in the inner ear, 
cerebrospinal fluid (CSF) and brain tissues with nanoparticles was found to be better than 
intravenous administration. After intratympanic administration (IT) in guinea pigs, the 
distribution of drugs in the inner ear, cerebrospinal fluid (CSF) and brain tissues with 
nanoparticles was found to be better than intravenous administration. Pharmacodynamic 
studies have shown that nanoparticles significantly inhibit oxidative reactions and protect the 
brain from cerebral ischemia/reperfusion (I/R) damage by restoring superoxide dismutase 
(SOD) activity in both serum and brain tissues, as well as significantly reduce 
  
malondialdehyde (MDA) levels and nitric oxide synthase (NOS). Moreover, intratympanic 
administration did not cause cochlear function damage by preliminary toxicity examination. 
Moreover, according to preliminary toxicity examination, intratympanic administration did 
not cause cochlear function damage. These findings suggest that the PLGA nanoparticle-
based delivery system through inner ear administration is a promising candidate for delivering 
drugs to the brain for the treatment of brain diseases [34, 35]. 
 
 
 
 
CONCLUSION 
 
Otic drug applications are developing rapidly, especially for the inner ear, and many new 
chemicals are in the preclinical or clinical stages. Many of these compounds have the 
potential to produce promising results for the effective and targeted treatment of inner ear 
disorders. Since noise, ototoxic drugs, ischemia, infection, inflammation, mechanical trauma, 
and other movements have been shown to cause damage to the inner ear in preclinical studies, 
it is very important to develop applicable and safe methods for the targeted delivery of drugs 
to specific areas of the inner ear. Otic drug administration can be divided into systemic and 
local drug administration. Despite potential side effects, systemic drug delivery is a minimally 
invasive approach and is well suited for self-administration. Systemic administration therefore 
continues to play an important role in the delivery of otic drugs. Local drug delivery can also 
be classified as topical, intratympanic and intralocal. Local drug delivery has the unique 
advantages of achieving high therapeutic concentration in the ear and minimizing systemic 
side effects. The most appropriate drug delivery route should be optimized taking into account 
for the disease, possible side effects and the patient's needs.The development of otic 
formulations should follow aforementioned basic formulation principles to provide effective 
and specific treatment for each type of ear disease. Although many difficulties in developing 
otic drugs continue, the sustained progress towards understanding the biology of the ear has 
led to the development of new drug delivery systems, including hydrogels, nanoparticles, and 
other minimally invasive drug delivery methods. These delivery systems offer better 
treatment options for individuals with side effects and a better quality of life for people 
suffering from ear diseases. Significant improvements in the study of drug release from otic 
dosage forms will encourage further studies in this area. 
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